Compare TDF & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TDF | CABA |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.0M | 319.6M |
| IPO Year | N/A | 2019 |
| Metric | TDF | CABA |
|---|---|---|
| Price | $11.21 | $4.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 49.1K | ★ 2.9M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.09 | $1.11 |
| 52 Week High | $12.20 | $4.05 |
| Indicator | TDF | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 52.16 | 71.77 |
| Support Level | $11.01 | $2.11 |
| Resistance Level | $11.41 | N/A |
| Average True Range (ATR) | 0.25 | 0.28 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 33.75 | 97.19 |
Templeton Dragon Fund Inc is a closed-end management investment company. The fund seeks long-term capital appreciation by investing majority of its total assets in equity securities of China companies. It invest in various sectors such as gas & consumable fuels, auto components, banks, beverages, communications equipment, healthcare equipment & supplies, restaurants & leisure, household durables and many others.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.